Electromedical Technologies, Inc. (ELCQ)


Electromedical Technologies 2019 Highlights and Outlook for 2020

Scottsdale, AZ – January 14, 2020 – Electromedical Technologies Inc. (OTC: ELCQ) (the “Company), the developer and manufacturer of WellnessPro Plus™ therapeutic medical device, is pleased to provide this corporate update summarizing its business to date, and its goals for 2020.


The Company develops and manufactures proprietary medical devices targeting physical pain relief. The Company’s flagship product is the WellnessPro Plus™, developed in 2007. The WellnessPro Plus™ is a portable device designed to deliver localized pain relief, supplied by its distribution of calibrated electrical energy pulses.


The Company’s mission is to develop, market and raise awareness of using electronic pulse therapies as a possible effective replacement or possible complement to current drug therapies targeting pain relief.


The Company’s proprietary technology in the WellnessPro Plus™ is based on its unique energy delivery system called DeepPulse™.  DeepPulse™ delivers a low voltage current to treat localized pain, and the Company believes that it provides longer lasting and more effective pain relief than many drugs and other products on the market.


The WellnessPro Plus™ received FDA clearance on July 6, 2007, as a Class II Medical Device, pursuant to the Company’s FDA clearance granted under section 510(K). The intended use of the WellnessPro Plus™  is for the treatment chronic intractable and acute pain, and as an adjunctive treatment for post-surgical and post-traumatic acute pain. The WellnessPro Plus™ is also qualified to be sold and used in Mexico.


The WellnessPro Plus™ was found to meet device safety standards for Radiated Emissions, Electrostatic Discharge, Radiated Immunity and device safety.


Today, many patients use the WellnessPro Plus™ in a variety of settings by healthcare professionals, athletes, coaches and others.


Commenting on the WellnessPro Plus™, the Company’s President and Principal Executive Officer, Matthew Wolfson, observed:


“A new era and a new category of medicine is emerging in the way we treat chronic pain. By learning to read and correct the electrical signals that travel between the brain and the body’s organs, we believe that a whole new frontier in treating chronic and acute pain will become reality in the not too distant future.  By using energy, frequency and vibration, we want to unlock the body’s natural ability to achieve wellness, better health and a better quality of life. The WellnessPro Plus™ device provides variable and rotating frequencies that we believe triggers endorphin release, which helps to relieve chronic and acute pain without the use of drugs“.


The Company’s 2019 Achievements


The Company completed Regulation A+ Tier II offering; filed 15C-211 with FINRA to commence trading; and listed on the OTC Markets Pink Tier under ticker Symbol “ELCQ.” The Company completed an independent audit of its financials and filed a registration statement with the Securities and Exchange Commission on November 12, 2019, and is working on addressing comments from the Commission, with the goal of becoming a fully reporting company under the Securities Act.


The Company’s Goals for 2020


The Company is actively engaged in research and development efforts on a new device it is calling the “WellnessPro Pod.” The Company envisions this device to provide more portability and features. The Company’s research and development’s goals for the “WellnessPro Pod” will be to expand the therapeutic uses for the Company’s technology, and to determine whether its technology may be helpful in other possible areas of treatment, such as PTSD, insomnia, depression, and anxiety. The Company also intends to pursue research and development to incorporate laser technology into its products that may allow the Company to enter the cosmetic applications market.


The Company also intends to extend its marketing outreach to wellness centers, targeting venues with significant patient traffic. The Company also expects to qualify its products for use in the European Union and Canada, further expanding its available markets.




The FDA’s issuance of a 510(k) clearance as a Class II Medical Device does not mean that FDA has made a determination that the Company’s device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.


Forward-Looking Statements


This news release contains “forward-looking statements,” which are not purely historical and may include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities and words such as “anticipate,” “seek,” “intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our Form S1, and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.


For more information, please visit the Company’s website at:



Toll free: 888-880-7888


SOURCE:  Electromedical Technologies, Inc.

About Electromedical Technologies

Since our company was founded, that philosophy has made us a leader in the worldwide electrotherapy market. Nothing makes us happier than knowing that our revolutionary device, the WellnessPro Plus, helps people around the world live happier, healthier, and more comfortable lives. We are not just the maker of the #1 doctor-recommended electrotherapy device, we are one of the premier medical products and services companies in the world, period.


We set high standards in everything we do. We focus on the fundamentals and are relentless in attending to the details. We are passionate about raising the bar and leading the electrotherapy revolution in America.


Our Mission Has Always Been To End Chronic Pain

Since introducing the world to the WellnessPro Plus in 2007, ElectroMedical Technologies has been at the forefront of the alternative pain relief movement. We will continue to lead the electrotherapy revolution until everyone who lives with acute or chronic pain knows that a safe, non-toxic, and effective solution exists— the WellnessPro Plus.


This work started in 2002 when Founder Matthew Wolfson witnessed a family member enjoy pain relief from a basic electrotherapy device. In that moment, he decided that if his family could enjoy these results, everyone should have access to similar pain-relief.


Having built other lasting technology companies, Matt assembled a team of leading scientists to advance the technology and in 2007 — with FDA clearance — delivered the world’s first intelligent portable bioelectronic medicine device, the WellnessPro.


Today, ElectroMedical serves tens of thousands of customers across the globe who suffer from chronic or acute pain and remains the innovation pioneer in portable bioelectronic devices.


Our Partners

ElectroMedical Technologies continues to work with a wide range of scientists, physicians, medical professionals, and distributors to share our mission with the world. We wouldn’t achieve our success without them, and we want to take this space to say “thank you” to everyone who is working with us to reduce suffering related to chronic pain.


The WellnessPro Plus: Revolutionizing TENS And Electrotherapy

Over 80 million Americans live with moderate to severe pain resulting from an accident, disease, or disorder — and nearly 40% of them report being unable to find adequate pain relief. They often resort to toxic pharmaceuticals to suppress their pain, yet still feel hopeless in their quest to find a natural, effective, and long-lasting solution.


We can change that, together.

ElectroMedical Technologies has brought together leading biomedical researchers from around the world to improve upon existing transcutaneous electrical nerve stimulation (TENS) technology and bioelectrical therapy modalities.

The FDA-cleared WellnessPro Plus is leading safe, effective alternative pain management option for your patients, relying on the latest in bioelectronics breakthroughs. It has become the #1 recommended electrotherapy device among doctors for a reason.


Simple-to-use, non-toxic, and non-invasive, the WellnessPro Plus relieves pain symptoms and supports the body’s ability to heal itself. Our device delivers long-lasting pain relief even in the most difficult cases where other means have failed.


Don’t let pain control your patients’ lives. Give them relief by offering the WellnessPro Plus in your office.


Safer Than Today’s Drugs

Another reason more doctors are turning to Electrotherapy devices like the WellnessPro Plus is the devastating side effects that painkillers are causing globally, often creating a greater harm than the initial injury.


America has an addiction problem.

Prescription drugs are effective at reducing initial pain, but reports show both diminished capabilities over time and many significant, harmful side effects. The more we study long-term painkiller use, the greater the danger becomes.


Give your patients a way to address their pain while avoiding the troubles in what the Centers for Disease Control and Prevention (CDC) is calling America’s biggest epidemic: prescription drug abuse


Here are some alarming statistics about painkillers that highlight the importance of safe, all-natural alternative pain management medicines and modalities like electrotherapy.


Every Patient Deserves Safe, Healthy Treatment Options

Electrotherapy is used by people all around the world as a natural pain relief therapy. There are many benefits associated with electrical stimulation therapy, specifically with pain-relieving TENS devices like the WellnessPro Plus.

  • Long-lasting pain relief
  • Treat pain resulting from a large number of diseases and physical conditions
  • Zero chemical side effects or dependency
  • No dangers associated with long-term use
  • Can be used in the comfort of your home


If you’re in pain, talk to your doctor about electrotherapy. Also get more information about the WellnessPro Plus to discover all of the ways that it can help you with your pain.


The WellnessPro Plus challenges the toxic pharmaceutical approach to pain management. If you want to relieve your pain and lead a happier and healthier life without subjecting your body to the harmful effects of prescription painkillers, the WellnessPro Plus can help.


Source:  https://electromedtech.com/

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Electromedical Technologies, Inc. (ELCQ) current news coverage by the company.  FNMG HOLDS NO SHARES OF Electromedical Technologies, Inc. (ELCQ) This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.